Thousand Oaks Sleep Clinic’s Bongo RX EPAP System For OSA Treatment AnnouncedNovember 24, 2025 at 10:18 AM EST
Southern California Pulmonary and Sleep Disorders Medical Center (805-557-9930) announces the availability of Bongo RX, an FDA-cleared nasal therapy device for treating mild to moderate obstructive sleep apnea. ![]() Thousand Oaks, United States, November 24, 2025 -- Recognizing the challenges that many patients face with traditional sleep apnea treatments, Thousand Oaks-based Southern California Pulmonary and Sleep Disorders Medical Center has announced the availability of Bongo RX. The FDA-cleared device uses Expiratory Positive Airway Pressure (EPAP) technology to treat mild to moderate obstructive sleep apnea (OSA), offering an alternative for patients seeking different treatment options. More details can be found at https://sleepmd4u.com/bongo-sleep-apnea-therapy-device/ The clinic explains that Bongo RX is designed to help alleviate the effects of OSA through a unique mechanism. The device features nasal pillows that form a seal just inside the nose, with small valves that open and close during normal breathing. When a user exhales, the valves close and direct air through precisely sized openings, generating EPAP that keeps the airway open until the next inhalation begins. According to the American Academy of Sleep Medicine, approximately 30 million adults in the United States have sleep apnea, though many cases remain undiagnosed. The National Sleep Foundation reports that untreated OSA can increase the risk of high blood pressure, heart disease, and stroke, making effective treatment options increasingly important for patient health outcomes. Southern California Pulmonary and Sleep Disorders Medical Center notes that the addition of Bongo RX is intended to provide patients with more choices when addressing their sleep apnea. The device's compact design and ease of use make it suitable for travel and may appeal to those who have found other treatment methods challenging to maintain consistently. "We understand that every patient's sleep apnea journey is different, and what works for one person may not work for another," a clinic representative states. "Having multiple treatment options available allows us to work more effectively with patients to find approaches that fit their specific needs and lifestyles." Founded in 1984 as a single-bed facility, Southern California Pulmonary and Sleep Disorders Medical Center became one of the nation's first freestanding sleep laboratories accredited by the American Academy of Sleep Medicine in 1985. Now located at 317 S. Moorpark Road in Thousand Oaks, the facility serves patients throughout Southern California, including Malibu and Los Angeles. Dr. Popper holds Board Certification in Sleep Disorders Medicine from both the ABSM and the ABIM. "Dr. Popper is an exceptional sleep specialist who makes you feel confident about your treatment plan," one patient recently stated. "He's friendly, caring, and always takes time to answer questions thoroughly. You leave knowing you're in good hands." Interested parties can find more information by visiting https://sleepmd4u.com/ Contact Info: Source: PressCable Release ID: 89176746 In the event of detecting errors, concerns, or irregularities in the content shared in this press release that require attention or if there is a need for a press release takedown, we kindly request that you inform us promptly by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will promptly address your feedback within 8 hours and take necessary actions to resolve any identified issues diligently or guide you through the removal process. Providing accurate and dependable information is our utmost priority. More NewsView More
Wall Street’s Sleeping Giant: Is Amazon About to Wake Up? ↗
December 02, 2025
Via MarketBeat
Checkmate in the Cloud: ServiceNow's Shopping Spree ↗
December 02, 2025
Via MarketBeat
The Contrarian Case for MSTR Amid MSCI Delisting Debacle ↗
December 02, 2025
Via MarketBeat
Tickers
MSTR
Worried About Mag 7 Concentration Risk? This ETF Could Help ↗
December 02, 2025
Dell Just Hit a Record in AI Orders—But the Real Test Starts Now ↗
December 02, 2025
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|
